These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 23796569)

  • 1. Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients.
    Klose M; Marina D; Hartoft-Nielsen ML; Klefter O; Gavan V; Hilsted L; Rasmussen AK; Feldt-Rasmussen U
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3802-10. PubMed ID: 23796569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R; Feldt-Rasmussen U; Mattsson AF; Monson JP; Bengtsson BA; Góth MI; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
    Agha A; Walker D; Perry L; Drake WM; Chew SL; Jenkins PJ; Grossman AB; Monson JP
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):72-7. PubMed ID: 17201804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy.
    Claessen KM; Appelman-Dijkstra NM; Adoptie DM; Roelfsema F; Smit JW; Biermasz NR; Pereira AM
    J Clin Endocrinol Metab; 2013 Jan; 98(1):352-61. PubMed ID: 23162104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine.
    Koulouri O; Auldin MA; Agarwal R; Kieffer V; Robertson C; Falconer Smith J; Levy MJ; Howlett TA
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):744-9. PubMed ID: 21521256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database.
    Attanasio AF; Bates PC; Ho KK; Webb SM; Ross RJ; Strasburger CJ; Bouillon R; Crowe B; Selander K; Valle D; Lamberts SW;
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1600-6. PubMed ID: 11932289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of thyroxine replacement on serum IGF-I, IGFBP-3 and the acid-labile subunit in patients with hypothyroidism and hypopituitarism.
    Schmid C; Zwimpfer C; Brändle M; Krayenbühl PA; Zapf J; Wiesli P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):706-11. PubMed ID: 17121519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting and postprandial lipid abnormalities in hypopituitary women receiving conventional replacement therapy.
    al-Shoumer KA; Cox KH; Hughes CL; Richmond W; Johnston DG
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2653-9. PubMed ID: 9253349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients.
    Filipsson H; Monson JP; Koltowska-Häggström M; Mattsson A; Johannsson G
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3954-61. PubMed ID: 16895963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.
    Deepak D; Daousi C; Javadpour M; Clark D; Perry Y; Pinkney J; Macfarlane IA
    Growth Horm IGF Res; 2010 Jun; 20(3):220-5. PubMed ID: 20185347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated leptin concentrations in growth hormone-deficient hypopituitary adults.
    al-Shoumer KA; Anyaoku V; Richmond W; Johnston DG
    Clin Endocrinol (Oxf); 1997 Aug; 47(2):153-9. PubMed ID: 9302387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum free thyroxine concentration is associated with metabolic syndrome in euthyroid subjects.
    Mehran L; Amouzegar A; Tohidi M; Moayedi M; Azizi F
    Thyroid; 2014 Nov; 24(11):1566-74. PubMed ID: 25069017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
    Florakis D; Hung V; Kaltsas G; Coyte D; Jenkins PJ; Chew SL; Grossman AB; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):453-9. PubMed ID: 11012570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency.
    Benedini S; Dalle Carbonare L; Albiger N; Scanarini M; Bilora F; Petrobelli F; Giannini S; Mantero F; Scaroni C
    Horm Metab Res; 2006 Jan; 38(1):16-21. PubMed ID: 16477535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
    Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement.
    Attanasio AF; Mo D; Erfurth EM; Tan M; Ho KY; Kleinberg D; Zimmermann AG; Chanson P;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):74-81. PubMed ID: 19897679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
    Monson JP; Jönsson P; Koltowska-Häggström M; Kourides I
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):623-8. PubMed ID: 17581260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects.
    Roos A; Bakker SJ; Links TP; Gans RO; Wolffenbuttel BH
    J Clin Endocrinol Metab; 2007 Feb; 92(2):491-6. PubMed ID: 17090642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.